Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.48 |
| ▸ | MMP8 | P22894 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733017 | 1.00 | MMP9 (0.48) | MMP9MMP8MMP2ADAM17MMP1 | |
| SCHEMBL6738452 | 0.89 | MME (0.48) | MMP9MMP2MMP1MMP13LARS1 | |
| SCHEMBL6738450 | 0.89 | MME (0.48) | MMP9MMP2MMP1MMP13LARS1 | |
| SCHEMBL6739658 | 0.83 | TSHR (0.45) | MMP9MMP8MMP2ADAM17MMP1 | |
| SCHEMBL6739657 | 0.83 | TSHR (0.45) | MMP9MMP8MMP2ADAM17MMP1 | |
| SCHEMBL6741426 | 0.83 | CTSB (0.43) | MMP9MMP8MMP2ADAM17MMP1 | |
| SCHEMBL6741428 | 0.83 | CTSB (0.43) | MMP9MMP8MMP2ADAM17MMP1 | |
| SCHEMBL1770896 | 0.80 | LARS1 (0.62) | MMP9MMP2ADAM17MMP1MMP13 | |
| SCHEMBL7948476 | 0.80 | LARS1 (0.62) | MMP9MMP2ADAM17MMP1MMP13 | |
| SCHEMBL6738793 | 0.79 | MEP1B (0.45) | MMP9MMP8ADAM17MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | claimed |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | MMP9 964/4885MMP8 1071/4885MMP2 689/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | MMP9 1073/4885MMP8 1161/4885MMP2 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.